{"links":{"feed":"https://www.erudio.com/reports/luosicns-nct03769103/feed.json","html":"https://www.erudio.com/reports/luosicns-nct03769103","json":"https://www.erudio.com/reports/luosicns-nct03769103.json","markdown":"https://www.erudio.com/reports/luosicns-nct03769103.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"luosicns-nct03769103"}},"request":"https://www.erudio.com/contact?report=luosicns-nct03769103"},"offer":{"cited_clinicians":6,"cited_commentary_sources":11,"verified_hcp_statements":39,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":10},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"luosicns-nct03769103"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=luosicns-nct03769103","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/luosicns-nct03769103","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 39 verified statements · 12 from 6 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-22T08:49:52.619354Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":0},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":5,"title":"Primary endpoint: Intracranial progression free survival"},{"claim_count":12,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":9,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":11,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":7,"title":"The comparison"},{"claim_count":7,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":6,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":4,"coverage":"discussed","id":"A1","source_count":3,"title":"MRI surveillance and salvage-SRS timing"},{"claim_count":3,"coverage":"discussed","id":"A2","source_count":1,"title":"CNS-risk stratification and patterns of failure"},{"claim_count":4,"coverage":"discussed","id":"A3","source_count":2,"title":"Evidence expansion and feasibility of further trials"},{"claim_count":3,"coverage":"discussed","id":"A4","source_count":2,"title":"Guideline alignment and interpretation of the prior evidence gap"}],"counts":{"cited_clinicians":6,"cited_clinicians_by_role":{"physician, Medical oncology":4,"physician, Radiation oncology":2},"cited_physicians":6,"cited_sources":12,"claims_by_expression_type":{"comparison":1,"experience":2,"interpretation":13,"opinion":10,"primary_context":3,"question":1,"restatement":5,"uncertainty":4},"claims_by_kind":{"objective_result":1,"protocol_statement":1,"publication_statement":2,"source_observation":35},"clinician_statements":12,"evidence_units":30,"findings":5,"organisational_accounts":2,"people_cited":13,"people_identity_verified":10,"people_total":13,"screened_sources":21,"verified_claims":39},"findings_index":[{"cited_clinicians":2,"id":"F1","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":1,"views":10},"limitations":4,"links":{"context":1,"support":14},"ma_question":true,"named_voices":5,"passages":10,"sources":7,"sources_by_kind":{"commentary":5,"media":1,"publication":1}},"title":"SRS timing: how speakers choose upfront use or deferral with close MRI follow-up","title_holders":{"cited_claim_ids":["claim-55eecc7c564c6acb6d50","claim-36c9b325ad56fcaced95","claim-14ab24a708414d465ac4","claim-4de47ea3f86b1de95f45","claim-15ec97d198f7a1dc3897","claim-385e9e7c67f9bb38766e","claim-db88b91629fb4fe4a927","claim-39026a5a33467ad7a291"],"clinicians":false,"holders":5,"speakers":5,"view":"split"},"evidence_line":"13 statements from 5 speakers in 7 sources, 1 of them a podcast or video","holder_line":"5 of the 5 named speakers in this finding take a side on this question"},{"cited_clinicians":2,"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":4},"limitations":4,"links":{"context":0,"support":7},"ma_question":true,"named_voices":4,"passages":7,"sources":4,"sources_by_kind":{"commentary":3,"publication":1}},"title":"OS medians: where speakers split on how to interpret them","title_holders":{"cited_claim_ids":["claim-113b978c6566be3d1969","claim-385e9e7c67f9bb38766e","claim-da5864251390e0cb713c","claim-994c79f00226d9884ce3","claim-df0ae3f407094cad57ca"],"clinicians":false,"holders":4,"sides":[{"cited_claim_ids":["claim-113b978c6566be3d1969","claim-385e9e7c67f9bb38766e"],"holders":2},{"cited_claim_ids":["claim-da5864251390e0cb713c","claim-994c79f00226d9884ce3","claim-df0ae3f407094cad57ca"],"holders":2}],"speakers":4,"view":"split"},"evidence_line":"7 statements from 4 speakers in 4 sources","holder_line":"4 of the 4 named speakers in this finding take a side on this question: 2 on one side, 2 on the other"},{"cited_clinicians":1,"id":"F3","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":4},"limitations":5,"links":{"context":0,"support":7},"ma_question":true,"named_voices":4,"passages":5,"sources":5,"sources_by_kind":{"commentary":3,"media":1,"publication":1}},"title":"Added SRS: what speakers say","evidence_line":"7 statements from 4 speakers in 5 sources, 1 of them a podcast or video"},{"cited_clinicians":1,"id":"F4","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":1,"views":3},"limitations":4,"links":{"context":1,"support":5},"ma_question":true,"named_voices":1,"passages":3,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"Upfront SRS: a clinician favors systemic therapy first but discusses high-risk cases","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-21918d9798f8af817ee4","claim-44bb32d04beaddf17dee"],"clause":"discuss high-risk cases","holders":1},"cited_claim_ids":["claim-44bb32d04beaddf17dee"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"5 statements from 1 speaker in 2 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “discuss high-risk cases”"},{"cited_clinicians":2,"id":"F5","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":1,"questions":3,"restated":3,"views":4},"limitations":5,"links":{"context":1,"support":11},"ma_question":true,"named_voices":5,"passages":9,"sources":6,"sources_by_kind":{"commentary":4,"media":1,"publication":1}},"title":"STARLET: most speakers question precision, but one sees it changing practice","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-6a9298cf444c8e2c8713"],"clause":"one sees it changing practice","holders":1},"cited_claim_ids":["claim-718fe8a86f07ea44cf16","claim-f5f149b145a4ef28f78d","claim-0bf07f8aa47e76581632","claim-6ed921e30e4c29e10dfb"],"clinicians":false,"holders":4,"speakers":5,"view":"reading"},"evidence_line":"11 statements from 5 speakers in 6 sources, 1 of them a podcast or video","holder_line":"4 of the 5 named speakers in this finding hold this view; 1 of them holds its caveat, “one sees it changing practice”"}],"open_question":{"basis":"From finding F1 (13 statements from 5 speakers in 7 sources)","cited_claim_ids":["claim-4b91953cb31e026dfa81","claim-55eecc7c564c6acb6d50","claim-36c9b325ad56fcaced95","claim-14ab24a708414d465ac4","claim-4de47ea3f86b1de95f45","claim-15ec97d198f7a1dc3897","claim-b9930e89d4ebdf1ec337","claim-07d05a29a5e707cc8941","claim-385e9e7c67f9bb38766e","claim-d038ef5a75ce6dc21d84","claim-db88b91629fb4fe4a927","claim-39026a5a33467ad7a291"],"finding_ids":["F1"],"question":"In treatment-naïve EGFR-mutated NSCLC with brain metastases, what do clinicians say remains unresolved when choosing upfront SRS plus osimertinib versus osimertinib with MRI surveillance and SRS at progression, including symptomatic or high-burden disease and prevention of long-term neurocognitive impairment?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One LinkedIn account reads STARLET as changing SRS timing, not eliminating radiotherapy"},{"id":"section-2","level":2,"title":"Some accounts find the survival medians persuasive; others limit the inference"},{"id":"section-3","level":2,"title":"One interview speaker reports their own quality-of-life findings as support for selective SRS deferral"},{"id":"section-4","level":2,"title":"One account combines systemic-first care with risk-adapted radiotherapy discussion"},{"id":"section-5","level":2,"title":"Speakers question precision; one interview speaker calls their studies “practice-changing”"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":3}],"id":"T1","label":"Primary endpoint: Intracranial progression free survival"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":4},{"id":"F5","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":7}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-22T08:49:52.619354Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-22T09:04:06Z","record_hash":"4bb0d3c1723a7123ffd7b1ea166215af56066a72c23876750ddc545b737d6185","release_hash":"774781f4a4077c9fac3d70643c79194b8f3ff3d7353439c25672c12417de8f24","report_id":"erudio-nct03769103","run_id":"5faa2965-41a7-4168-9ba6-365cc56a19e8","schema_version":"5.0","slug":"luosicns-nct03769103","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"One speaker reads LUOSICNS within STARLET as supporting osimertinib first with close MRI surveillance, citing SRS use at progression, but does not extend that reassurance to symptomatic disease or greater intracranial burden. A medical oncologist would selectively consider upfront SRS plus osimertinib because of the survival signal, while another stresses that the difference was not statistically significant. Long-term neurocognitive protection remains unresolved.","examples":[],"meta_description":"21 sources screened · 39 verified statements (12 from clinicians verified by NPI or staff page) from 12 sources · 5 findings. Updated Nov 22, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-22T09:04:06Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":21},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","12 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 36 sources about other trials or topics are not included; discussion that refers to the trial only by a name it shares with other things may be missing.","The sources reviewed for this edition do not represent all HCPs or all public discussion. Discussion without explicit trial names or with different transcription variants may be missing, and some potentially relevant discussions were not examined in full.","Publication-linked posts, replies, conference reporting and the interview are not interchangeable or necessarily independent assessments. Reposts do not establish endorsement.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The pooled publication reports 79 randomized participants, while a speaker says 80 in the interview account of their own study. Neither total should be substituted for the other without explanation.","The publication abstract reports OS medians without an OS significance test. Statements about OS nonsignificance, power and the reason for uncertainty remain attributed to their speakers.","The quality-of-life discussion concerns specified patient-reported domains; it does not establish objective neurocognitive equivalence or prevention of late impairment.","A speaker's risk associations and treatment interpretation come from a separate retrospective study and cannot establish which patients benefit from upfront SRS or WBRT.","A standalone protocol was not available in the sources reviewed, limiting assessment of protocol details beyond the publication and registry context.","Earlier comments that outcomes were awaited are dated historical views, not statements that STARLET results remain unavailable."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":3,"other":0,"podcast":0,"publication":1,"registry":0,"regulatory":0,"x_thread":7,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":11,"results":1},"count":12,"evidence_window":{"end":"2026-11-01","start":"2023-06-01"},"retrieval_snapshot":"2026-11-22T07:15:23.189466Z","timeline":[{"count":1,"week":"2023-W22"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2024-W37"},{"count":3,"week":"2026-W03"},{"count":1,"week":"2026-W04"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT03769103:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03769103:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:41534788","quote_policy":"short_quote_link_out"},{"id":"openfda:5e81b4a7-b971-45e1-9c31-29cea8c87ce7:20260914","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-6eluc424ihv4p3u4cqhzk7rm-3mcrl6occ6c2m","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-6eluc424ihv4p3u4cqhzk7rm-3mm4v4gguu22t","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-bmtbr3qhqopshkscgdwcwrar-3mcvchsc4322v","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7418203493661900800","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7420519713778229248","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7522797728112926720","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1664182142580973568:6c388bcc-002b-4ccf-a117-e88767c0e01f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701495904966971395:5e395e89-a394-4479-94d7-3883e239bfec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701528206040539269:cd4aa16d-e862-4974-b799-591ac8c65099","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1772688442297651401:ba4434ee-8438-46df-9330-9b0d699f3681","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1831533394339172406:5f2fdca5-38de-4cc1-b345-03e9deba2da5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833215568775942372:6c768da9-4842-4927-8f21-717968532206","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979167932291653712:349d00d5-a0f5-4c72-b289-ab5b85470f9d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2010881757110022532:775cf497-4111-4cc1-a790-fed986a42e66","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011487136726364378:9c0dd0d8-bde1-49bd-92f9-d3c8241a7fde","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011634524648862154:e0edf13d-6c68-4fbd-ba4c-4bd74d0a893a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052936473523966316:2e1be197-54ad-4d5e-b819-613f512b4eaa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2054209194245460336:9afea343-2c4c-4e3d-922a-d58593d662f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093694753326166220:a608d24f-5dd6-4e43-86ca-755ad39c7cfe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093696096321069094:9409afbc-6612-4978-919b-eebe34c60150","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:iBJSwqpZAlQ","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":3,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":14,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":21},"count":21,"evidence_window":{"end":"2026-11-01","start":"2023-06-01"},"retrieval_snapshot":"2026-11-22T07:15:23.189466Z","timeline":[{"count":1,"week":"2023-W22"},{"count":2,"week":"2023-W37"},{"count":1,"week":"2024-W13"},{"count":1,"week":"2024-W36"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2025-W42"},{"count":4,"week":"2026-W03"},{"count":3,"week":"2026-W04"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W21"},{"count":2,"week":"2026-W35"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W44"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":15,"other":0,"podcast":0,"publication":4,"registry":0,"regulatory":0,"x_thread":13,"x_video":0,"youtube":7}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Tagrisso"],"label":"osimertinib","slug":"osimertinib"}],"indications":[{"reason":"Unmapped registry condition: Lung Cancer Non-small Cell Stage IV","status":"unmapped"},{"reason":"Unmapped registry condition: Brain Metastases","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"LUOSICNS","aliases":["LUOSICNS","Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC","Open Label, Multicenter, Phase II Study of Patients With Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone"],"brief_title":"Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC","collaborators":["AstraZeneca","Princess Margaret Hospital, Canada","Sunnybrook Health Sciences Centre"],"conditions":["Lung Cancer Non-small Cell Stage IV","Brain Metastases"],"display_condition":"treatment-naïve EGFR-mutated NSCLC with brain metastases","display_interventions":[["osimertinib"]],"enrollment":{"count":40,"type":"ACTUAL"},"interventions":[{"name":"Osimertinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Stereotactic radiotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"}],"nct_id":"NCT03769103","official_title":"Open Label, Multicenter, Phase II Study of Patients With Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone","overall_status":"UNKNOWN","phase":["PHASE2"],"primary_completion_date":{"date":"2025-04","type":"ESTIMATED"},"primary_endpoints":[{"description":"Absence of progressive brain metastases according to the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM criteria)","measure":"Intracranial progression free survival","timeFrame":"1 year"}],"registered_date":{"date":"2018-12-07","type":"ACTUAL"},"registry_last_updated":"2024-10-31","registry_url":"https://clinicaltrials.gov/study/NCT03769103","short_name":"LUOSICNS","short_name_basis":"canonical_name","sponsor":"British Columbia Cancer Agency","start_date":{"date":"2019-03-19","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"LUOSICNS","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}